Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
145
self-reported band not used
Founded
2014
12 years
Legal entities
1
ACRA
Office countries
1
2 addresses
Funding rounds
5
Debt financing · Feb 2025 · US$ 40.0M
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
MIRXES PTE. LTD.Entity record →
UEN201407328H
Legal entities
Show as table · Mirxes: 1 registry entity
| MIRXES PTE. LTD. | UEN 201407328H |
|---|---|
| Confirmed matches | 1 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum.
We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide.
Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers.
We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey.
MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics.
Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases.
We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.
Specialties
All 19 specialties
- miRNA
- qPCR
- Diagnostics
- Cancer
- Liquid Biopsy
- microRNA
- Early Cancer Detection
- Disease Diagnostics
- Contract Development and Manufacturing
- Research and Development
- ISO13485 Manufacturing
- In vitro diagnostics
- miRNA Profiling
- Research Collaborations
- Biotech
- Agri-tech
- Vet-tech
- Insurtech
- Medical Devices
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | SG |
All codes: SG
Addresses
- SG2 Tukang Innovation Grove, JTC MedTech Hub, #09-02; Singapore, 618305Primary
- SG3 Biopolis Dr; #01-15 Synapse; Singapore, Singapore 138623
Grid intelligence Members
Funding
Rounds5
Round typeDebt financing · non-equity funding
Amount (USD)40,000,000
Stage ranknot recorded
Investors named1
Since last round11 mo
Funding
Show as table · 5 funding rounds
| Rounds | 5 |
|---|---|
| Axis | 2014 to 2026 |
| Debt financing · 13 Feb 2025 | US$ 40.0M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entity operates under Mirxes?
One Singapore entity on ACRA: MIRXES PTE. LTD. (UEN 201407328H), high confidence.
How many people work at Mirxes?
145 counted staff profiles at January 2026. The brand's self-reported band sits above that count and is not published as a headcount.
Where does Mirxes have offices?
Two addresses on record, Singapore only. Primary: 2 Tukang Innovation Grove, JTC MedTech Hub, #09-02, Singapore 618305.
Has Mirxes raised funding?
Five rounds. Latest 13 February 2025: debt financing, US$40,000,000, investor R-Bridge.
What does Mirxes list as its specialties?
19 tags on the brand's own list, among them research and development, biotech and cancer.
Which companies are listed alongside Mirxes?
Six peer profiles on record: Hilleman Laboratories and NalaGenetics.